Clinical trials: Rivaroxaban
Atrial Fibrillation
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others.
- Trial name
- COBRRA-AF (NCT04642430)
- Testing
- Apixaban, Rivaroxaban
- Where
- 8 sites in Canada
- Volunteers
- 3,018 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thrombosis
Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated…
- Trial name
- BOX-DVT (NCT01855100)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Belgium
- Volunteers
- 131 people
- Sponsor
- Bayer
Venous Thromboembolism
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events.
- Trial name
- EINSTEINJr (NCT02309411)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 29 sites in United States, Australia and 13 more
- Volunteers
- 46 people
- Sponsor
- Bayer
Anticoagulants and Thrombotic Disorders
Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients
Direct oral anticoagulants (DOACs) are now recommended as a first-line option in cancer patients with venous thromboembolism or atrial fibrillation.
- Trial name
- EPRAPAC (NCT05819736)
- Testing
- Monitoring
- Where
- France
- Volunteers
- 193 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Osteoarthritis, Knee
Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty
Our purpose of this study therefore is to conduct a prospective randomized controlled trial to investigate the blood-conservation effect of combined topical application of these two hemostatic agents in different time during…
- Trial name
- NCT03328832
- Testing
- Topical tranexamic acid, Floseal®, rivaroxaban (10mg)
- Where
- Taiwan
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Atrial Fibrillation
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
This international study is a prospective noninterventional observational cohort study of patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or…
- Trial name
- XANTUS-EL (NCT01800006)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 17 sites in Argentina, Azerbaijan and 15 more
- Volunteers
- 2,101 people
- Sponsor
- Bayer
Nonvalvular Atrial Fibrillation
AntiCoagulants and COGnition
The purpose of this study is to compare the change of global cognitive performance after 52 weeks of intervention among participants with nonvalvular atrial fibrillation (NVAF) receiving rivaroxaban versus a vitamin K antagonist…
- Trial name
- ACCOG (NCT04073316)
- Testing
- Rivaroxaban 20 MG, Warfarin
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Angers
Atrial Fibrillation, Periodontal Disease
Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
The purpose of this study is to evaluate the safety of a protocol which does not suspend the new oral anticoagulants (dabigatran, rivaroxaban and apixaban) in front of dental extractions in patients with non-valvular atrial…
- Conditions
- Atrial Fibrillation, Periodontal Disease, Hemorrhage
- Trial name
- NCT03181386
- Testing
- Rivaroxaban, Dabigatran and Apixaban, Warfarin
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo General Hospital
Rivaroxaban, Cancer-associated Thrombosis
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Rivaroxaban has been developed in the various clinical settings, prevention of venous thromboembolism (VTE)after major orthopedic surgery, prevention of stroke in atrial fibrillation, and in the treatment of acute coronary…
- Conditions
- Rivaroxaban, Cancer-associated Thrombosis, Recurrence, Bleeding
- Trial name
- NCT01989845
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Seoul National University Hospital
Intracranial Hemorrhages
Andexanet Alfa: Non-interventional Study in Stroke Units in Germany (DE)
The multicenter, prospective, observational, non-interventional study conducted in German Stroke Units is investigating patients with intracranial hemorrhage (ICH) under effective anticoagulation with rivaroxaban or apixaban.
- Trial name
- ASTRO-DE (NCT05127941)
- Where
- 2 sites in Germany
- Volunteers
- 141 people
- Sponsor
- University Hospital, Essen
Cerebral Venous Thrombosis
Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis
Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed…
- Trial name
- NCT06531122
- Testing
- Apixaban 5MG, Rivaroxaban 20 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Kafrelsheikh University
Drug Drug Interaction Study
Rivaroxaban Sotorasib Interaction Study
Venous thromboembolic Events (VTEs) are common in lung cancer patients with an incidence of >15%, requiring anticoagulant treatment or prophylaxis.
- Trial name
- ROSIE (NCT06314763)
- Testing
- Rivaroxaban 20mg, Sotorasib 960mg
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Atrial Fibrillation, Cardioversion
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between…
- Conditions
- Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke
- Trial name
- AFTER-CV (NCT01924065)
- Testing
- Cardioversion, Oral Anticoagulant
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Suleyman Demirel University
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
Anticoagulants, Thromboembolism
Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
Vitamin K antagonists were hampered by several disadvantages, such as the need for frequent monitoring. In this context, new oral anticoagulants (NOACs) have been developed and are now available on the market.
- Conditions
- Anticoagulants, Thromboembolism, Hemorrhage
- Trial name
- Pgp NACO (NCT02103101)
- Testing
- Measurement of Plasma Concentrations of NOACs, Identification of ABCB1 polymorphisms coding for P-gp
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)
DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial
People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people.
- Trial name
- SWITCH-AF (NCT07011095)
- Testing
- VKA, Direct Oral Anticoagulant (DOAC)
- Volunteers
- 100 people
- Sponsor
- Population Health Research Institute
Atrial Fibrillation
Polish Atrial Fibrillation (POL-AF) Registry
Evaluation of clinical characteristics and pharmacotherapy of hospitalized Polish patients with atrial fibrillation (AF).
- Trial name
- POL-AF (NCT04419012)
- Testing
- observation
- Where
- Poland
- Volunteers
- 4,000 people
- Sponsor
- Jan Kochanowski University
Bleeding Post Cardiac Surgery, Indication for Anticoagulation
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with…
- Trial name
- DANCE (NCT04284839)
- Testing
- DOAC, VKA
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 3,500 people
- Sponsor
- Population Health Research Institute
Hip Arthroplasty, Total, Prevention of Venous Thromboembolism
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
Surgical hip replacement (total hip arthroplasty, THA) is associated with a high risk of venous thromboembolism, but the appropriate duration of postoperative medical thromboprophylaxis ("anticoagulation") remains highly…
- Trial name
- ENABLE-Hip (NCT06611319)
- Testing
- Prevention of Venous Thromboembolism
- Where
- 6 sites in Austria, Germany
- Volunteers
- 2,932 people
- Sponsor
- Prof. Stavros Konstantinides, MD
Venous Thromboembolism
Statin Use in Patients With Acute VTE
This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with atorvastatin given at 40 mg orally daily for 3…
- Trial name
- NCT02331095
- Testing
- Atorvastatin, Anticoagulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University